Mar 19 |
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
|
Mar 19 |
Seelos drops as lead drug fails in ALS trial
|
Mar 19 |
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
|
Mar 19 |
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
|
Mar 7 |
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation
|
Jan 27 |
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
|
Jan 26 |
Seelos Therapeutics announces equity and warrants offering for gross proceeds of $4M
|
Jan 26 |
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
Jan 22 |
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
|
Jan 12 |
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
|